Format

Send to

Choose Destination
Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70. doi: 10.1586/17512433.2016.1172960.

Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).

Author information

1
a Department of Pathology, Microbiology & Immunology , Vanderbilt University , Nashville , USA.

Abstract

Chronic fatigue syndrome/ Myalgic encephalomyelitis (CFS/ME) is a poorly understood seriously debilitating disorder in which disabling fatigue is an universal symptom in combination with a variety of variable symptoms. The only drug in advanced clinical development is rintatolimod, a mismatched double stranded polymer of RNA (dsRNA). Rintatolimod is a restricted Toll-Like Receptor 3 (TLR3) agonist lacking activation of other primary cellular inducers of innate immunity (e.g.- cytosolic helicases). Rintatolimod also activates interferon induced proteins that require dsRNA for activity (e.g.- 2'-5' adenylate synthetase, protein kinase R). Rintatolimod has achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled clinical trials with a generally well tolerated safety profile and supported by open-label trials in the United States and Europe. The chemistry, mechanism of action, clinical trial data, and current regulatory status of rintatolimod for CFS/ME including current evidence for etiology of the syndrome are reviewed.

KEYWORDS:

Ampligen; Rintatolimod; TLR3 agonist; chronic fatigue/myalgic encephalomyelitis; clinical efficacy; clinical safety; clinical trials; dsRNA; primate/non-primate disassociation of toxicity

PMID:
27045557
PMCID:
PMC4917909
DOI:
10.1586/17512433.2016.1172960
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center